ENTRY       D03260                      Drug
NAME        Vardenafil hydrochloride hydrate (JAN);
            Vardenafil monohydrochloride trihydrate;
            Levitra (TN);
            Staxyn (TN)
PRODUCT
  GENERIC   VARDENAFIL (Alembic Pharmaceuticals Limited)
            VARDENAFIL (Alembic Pharmaceuticals)
            VARDENAFIL (Aphena Pharma Solutions - Tennessee)
            VARDENAFIL (Aphena Pharma Solutions - Tennessee)
            VARDENAFIL (Golden State Medical Supply)
            VARDENAFIL (Macleods Pharmaceuticals Limited)
            VARDENAFIL (Zydus Lifesciences Limited)
            VARDENAFIL (Zydus Pharmaceuticals USA)
            VARDENAFIL HYDROCHLORIDE (Alembic Pharmaceuticals Limited)
            VARDENAFIL HYDROCHLORIDE (Alembic Pharmaceuticals)
            VARDENAFIL HYDROCHLORIDE (Amneal Pharmaceuticals NY LLC)
            VARDENAFIL HYDROCHLORIDE (Aphena Pharma Solutions - Tennessee)
            VARDENAFIL HYDROCHLORIDE (AvKARE)
            VARDENAFIL HYDROCHLORIDE (Bryant Ranch Prepack)
            VARDENAFIL HYDROCHLORIDE (Bryant Ranch Prepack)
            VARDENAFIL HYDROCHLORIDE (Bryant Ranch Prepack)
            VARDENAFIL HYDROCHLORIDE (Lannett Company)
            VARDENAFIL HYDROCHLORIDE (Macleods Pharmaceuticals Limited)
            VARDENAFIL HYDROCHLORIDE (Teva Pharmaceuticals USA)
FORMULA     C23H32N6O4S. 3H2O. HCl
EXACT_MASS  578.2289
MOL_WEIGHT  579.1098
CLASS       Cardiovascular agent
             DG01509  Phosphodiesterase V inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2590
            ATC code: G04BE09
            Chemical structure group: DG00487
            Product (DG00487): D03260<JP/US>
EFFICACY    Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor
COMMENT     Treatment of erectile dysfunction
TARGET      PDE5 [HSA:8654] [KO:K13762]
  PATHWAY   hsa04022(8654)  cGMP-PKG signaling pathway
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             G GENITO URINARY SYSTEM AND SEX HORMONES
              G04 UROLOGICALS
               G04B UROLOGICALS
                G04BE Drugs used in erectile dysfunction
                 G04BE09 Vardenafil
                  D03260  Vardenafil hydrochloride hydrate (JAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Sexual Disorder Agents
              Sexual Disorder Agents (Male)
               Vardenafil
                D03260  Vardenafil hydrochloride hydrate (JAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              25  Urogenital and anal organ agents
               259  Miscellaneous
                2590  Miscellaneous
                 D03260  Vardenafil hydrochloride hydrate (JAN)
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01509  Phosphodiesterase V inhibitor
               DG00487  Vardenafil
                D03260  Vardenafil hydrochloride hydrate
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00487  Vardenafil
                 D03260  Vardenafil hydrochloride hydrate
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Phosphodiesterases
                PDE5
                 D03260  Vardenafil hydrochloride hydrate (JAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03260
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03260
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03260
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03260
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D03260
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01509  Phosphodiesterase V inhibitor
               DG00487  Vardenafil
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00487  Vardenafil
DBLINKS     PubChem: 17397413
            LigandBox: D03260
ATOM        38
            1   C8y C    20.3016  -19.5044
            2   C8y C    21.4944  -18.8028
            3   C8y C    20.3016  -20.9076
            4   C8x C    19.0388  -18.8028
            5   N4x N    22.6871  -19.5044
            6   N5x N    21.4944  -17.3996
            7   C8x C    19.0388  -21.6092
            8   O2a O    21.4944  -21.6092
            9   C8y C    17.8460  -19.5044
            10  N4y N    23.9500  -18.8028
            11  C8y C    22.6871  -16.6980
            12  C8x C    17.8460  -20.9076
            13  C1b C    22.6871  -20.9076
            14  S4a S    16.6533  -18.8028
            15  C8y C    23.9500  -17.3996
            16  C8y C    25.2830  -19.2238
            17  O5x O    22.6871  -15.2948
            18  C1a C    23.8798  -21.6092
            19  N1y N    15.4606  -19.5044
            20  O3c O    17.6356  -17.8206
            21  O3c O    15.6711  -17.8206
            22  C8y C    25.2830  -16.9786
            23  N5x N    26.1249  -18.1012
            24  C1b C    25.7040  -20.5568
            25  C1x C    15.4606  -20.9076
            26  C1x C    14.1977  -18.8028
            27  C1a C    25.7040  -15.6456
            28  C1b C    27.0370  -20.8374
            29  C1x C    14.1977  -21.6092
            30  C1x C    13.0050  -19.5044
            31  C1a C    27.4580  -22.1705
            32  N1y N    13.0050  -20.9076
            33  C1b C    11.8123  -21.6092
            34  C1a C    10.6195  -20.9076
            35  X   Cl   31.4575  -17.6833
            36  O0  O    31.6109  -19.7833
            37  O0  O    31.6109  -19.7833
            38  O0  O    31.6109  -19.7833
BOND        37
            1     1   2 1
            2     1   3 1
            3     1   4 2
            4     2   5 1
            5     2   6 2
            6     3   7 2
            7     3   8 1
            8     4   9 1
            9     5  10 1
            10    6  11 1
            11    7  12 1
            12    8  13 1
            13    9  14 1
            14   10  15 1
            15   10  16 1
            16   11  17 2
            17   13  18 1
            18   14  19 1
            19   14  20 2
            20   14  21 2
            21   15  22 2
            22   16  23 2
            23   16  24 1
            24   19  25 1
            25   19  26 1
            26   22  27 1
            27   24  28 1
            28   25  29 1
            29   26  30 1
            30   28  31 1
            31   29  32 1
            32   32  33 1
            33    9  12 2
            34   11  15 1
            35   22  23 1
            36   30  32 1
            37   33  34 1
BRACKET     1    29.3300  -20.6500   29.3300  -19.0400
            1    32.2700  -19.0400   32.2700  -20.6500
            1  3
  ORIGINAL  1   36
  REPEAT    1   37  38
///
